Wellspect Unveils Surity Catheter to Enhance Male Incontinence Care

MÖLNDAL, Sweden – April 30, 2026 – Wellspect HealthCare today announced the U.S. launch of its Surity™ Male External Catheter, a significant new entry into the urinary incontinence care market. The non-invasive device aims to provide a reliable and comfortable solution for the more than 13 million Americans living with severe urinary incontinence, a condition that poses daily challenges to both patients and their caregivers.

This launch marks the latest expansion of the company's Surity™ portfolio, which began earlier this year with the introduction of a female external catheter. Wellspect, a global subsidiary of Dentsply Sirona, is positioning the Surity™ line as a cornerstone of its strategy to address unmet needs in continence management, with a full Surity™ Urinary Management System anticipated to follow.

A New Standard in Patient-Centric Design

For millions of men, severe urinary incontinence profoundly disrupts daily life, leading to sleep disturbances, an increased risk of falls, skin breakdown, and significant emotional strain. The constant need for management can erode confidence and dignity. While external catheters are not new, patient feedback on existing options often highlights persistent issues with skin irritation, leakage, discomfort, and difficulty of use.

The Surity™ Male External Catheter was engineered to directly address these pain points. Developed with skin-friendly materials, the device is suitable for up to 24 hours of wear and is designed to move naturally with the body. Its most distinctive features include a transparent, see-through design that allows for easy placement and crucial visual skin checks, a slim profile to reduce bulk under clothing, and a soft, non-woven backing material intended to be gentle on the skin. By effectively diverting urine away from the body into a compatible collection system, the device offers a discreet and comfortable option for men managing their condition at home.

"By expanding the Surity™ portfolio to include solutions for both men and women living with severe urinary incontinence, we aim to help address a clear gap in incontinence care," said Chris Schlenk, Group Vice President at Wellspect HealthCare. "Our goal is to offer solutions designed to support comfort, rest, and confidence for people facing these challenges each day."

The patient-centric philosophy behind the portfolio is already showing promise. The Surity™ Female External Catheter, launched earlier, has garnered positive feedback for its ease of use and comfort. Dru Woodward, who uses the female device, shared her experience. "Surity™ has provided me with a practical option for my day-to-day life," she stated. "It is easy to place and has integrated seamlessly into my routines, helping me feel confident in the management of my care."

A Strategic Move in a Competitive Market

The launch is a calculated move into the robust and growing U.S. male external catheter market, which was valued at over $385 million in 2024 and is projected to exceed $627 million by 2032. The market's steady growth, fueled by an aging population and a strong clinical preference for non-invasive solutions, has attracted major medical device companies. Wellspect enters a competitive field with established players, but its focus on next-generation features positions it to capture a significant share.

Market trends show a clear shift away from traditional latex products toward advanced silicone catheters that are more breathable, flexible, and hypoallergenic. The Surity™ catheter's design, emphasizing skin health and user experience, aligns perfectly with this evolution. Its self-adhesive nature and anti-leak design principles are table stakes in the modern market, but the unique combination of a slim profile, transparent body, and soft backing material provides a compelling competitive advantage.

This strategic expansion is central to the mission of Wellspect and its parent company, Dentsply Sirona, which has identified continence care as a key high-growth category. By building out the Surity™ brand into a comprehensive product family for both men and women, Wellspect is solidifying its role as an innovator dedicated to improving quality of life.

Addressing a Broader Public Health Challenge

The impact of urinary incontinence extends far beyond individual discomfort. It is a significant public health issue associated with a cascade of related health problems, including dermatitis, an increased incidence of falls, and a higher risk of urinary tract infections. Furthermore, studies have linked the condition to increased rates of anxiety and depression, compounding the physical toll with a heavy emotional burden.

Innovations in non-invasive management are critical for mitigating these risks. External catheters are widely preferred over indwelling catheters, which carry a much higher risk of catheter-associated urinary tract infections (CAUTIs), a serious and costly complication in healthcare settings. By providing an effective external solution, products like the Surity™ catheter can help reduce infection rates and improve overall patient outcomes.

This launch also supports the broader trend toward home healthcare, empowering patients to manage chronic conditions with greater independence and dignity. For caregivers, who often bear significant physical and emotional strain, user-friendly devices that are easy to apply and monitor can dramatically reduce their daily burden.

The Surity™ Male External Catheter is now available for direct-to-consumer purchase online and will be rolled out to healthcare institutions in the near future. This product launch continues Wellspect's long history of pioneering advancements in continence care, which began with the introduction of the first hydrophilic-coated intermittent catheter, LoFric®, in 1983. With the expansion of the Surity™ portfolio, the company reaffirms its commitment to developing solutions that restore comfort and confidence for people managing complex continence needs.